Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06268093 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Therapeutic Effect of Thalidomide in Syringomyelia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in refractory syringomyelia. Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before thalidomide usage.
Trial Details
NCT Number NCT06268093
Lead Sponsor Xuanwu Hospital, Beijing
Conditions
(from sponsor)		 Syringomyelia, Thalidomide
Related terms Syringomyelia
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov